Faculty Opinions recommendation of Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial.
Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature